U.S., Oct. 2 -- ClinicalTrials.gov registry received information related to the study (NCT07850973) titled 'Phase 1/2 Study Of PARP Inhibition With Olaparib To Enhance The Efficacy Of High-Dose Chemotherapy In Refractory And Relapsed Germ Cell Tumors' on Sept. 28.
Brief Summary: The goal of this clinical research study is to find the highest safe dose of olaparib that can be combined with chemotherapy drugs and stem cell transplantation to treat patients with relapsed and refractory germ cell cancer. The safety and effectiveness of this treatment combination therapies will also be studied.
Study Start Date: March 01, 2027
Study Type: INTERVENTIONAL
Condition:
Germ Cell Cancer
Intervention:
DRUG: Olaparib
Given by mouth twice daily
...